EPP3: Investment in Sterile Injectables/Infusions by Kotra Pharma

0 comments


Kotra Pharma will be investing RM60 million to develop a manufacturing line to produce sterile injectable or infusion products. These products are currently not produced in Malaysia and it will be a pioneering initiative.
  • Investment by 2020 (million)
    RM60
  • GNI Impact by 2020 (million)
    RM35.2
  • Jobs created by 2020
    99
The manufacturing line will be an addition to the world class pharmaceutical plant worth RM152 million which was initiated in 2010.

Kotra will be able to supply the Ministry of Health through this investment which will then substitute the need to import these products. Kotra currently exports to over 40 countries to date and is looking to expand the product range in its export market.

Source: ETP website
 


About the Author

Many years in the Healthcare Industry, his extensive network and current active participations in various Projects with the Government and NGOs in policies formulation and input, development and implementation of strategies and action plans enable him to keep abreast with the changing, transforming roles and dynamism of the Industry and its ecosystem.

Post a Comment

Subscribe to: Post Comments (Atom)